Early discovery is the best way to treat cancer.
Statistics show that 5-year survival rates for common cancers such as breast cancer, ovarian cancer and prostate cancer are as high as 90% with early diagnosis and treatment, while the 5-year survival rate with late-stage diagnosis is around 30%.
Source: SEER Cancer Statistics, National Cancer Institute
Cancer is one of the leading causes of death, with a case being confirmed roughly every 6 minutes. Most cacners are caused by cellular changes that are hard to detect with conventional examination methods (including imaging and tumour markers), so it is important to track changes in malignant tumour cell DNA to effectively detect cancer at an early stage.
Modern technology allows us to test for traces of cancerous gene mutations in the bloodstream, effectively and accurately discovering precancerous pathological changes and kill cancer before it takes root. Circulating tumour DNA (ctDNA) is one of the most advanced techniques used in cancer prevention today and has the twin advantages of high accuracy and comprehensive detection. The key technologies involved are able to overcome the difficulties of detecting traces of changes in dead tumour cell DNA fragments, allowing us to achieve highly sensitive and integrated detection of cell-free genetic variations within the blood serum or plasma.
Our lab uses deep next generation sequencing (NGS) techniques that require just 10ml of blood and are capable of analysing 400,000 genetic loci covering 28 types of cancer in men and women. This allows you to estimate your risk of cancer at the earliest possible opporunity, helping you to take preventative action in a timely manner and massively increase your chances of successful treatment.
